The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials

Schizophr Res. 2008 Oct;105(1-3):208-15. doi: 10.1016/j.schres.2008.06.018. Epub 2008 Sep 14.

Abstract

Objective: To examine the efficacy of aripiprazole across symptoms in patients with acute exacerbation of schizophrenia or schizoaffective disorder.

Methods: Data were pooled from five, 4-6-week acute studies. PANSS Total, Positive, Negative, and General Psychopathology Subscale improvements were analyzed, as well as all 30 individual PANSS items.

Results: Aripiprazole had statistically significant decreases versus placebo on PANSS subscales at Week 4, similar to those seen with haloperidol. Aripiprazole-treated patients also showed significant decreases versus placebo in 26 of the 30 PANSS items (all p<0.05).

Conclusion: Aripiprazole demonstrates statistically and clinically significant efficacy across a range of symptoms in schizophrenia.

Publication types

  • Comparative Study
  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Antipsychotic Agents / therapeutic use*
  • Aripiprazole
  • Cognition Disorders / drug therapy
  • Cognition Disorders / psychology
  • Female
  • Humans
  • Male
  • Piperazines / therapeutic use*
  • Placebos
  • Psychiatric Status Rating Scales / statistics & numerical data
  • Quinolones / therapeutic use*
  • Randomized Controlled Trials as Topic / statistics & numerical data
  • Schizophrenia / diagnosis
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology*
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Piperazines
  • Placebos
  • Quinolones
  • Aripiprazole